Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial

IMPORTANCE: Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1–selected tumors. OBJECTIVE: To evaluate the safety and antitumor activity of the anti-TIGIT antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Won, Bedard, Philippe L., LoRusso, Patricia, Gordon, Michael S., Bendell, Johanna, Oh, Do-Youn, Ahn, Myung-Ju, Garralda, Elena, D’Angelo, Sandra P., Desai, Jayesh, Hodi, F. Stephen, Wainberg, Zev, Delord, Jean-Pierre, Cassier, Phillippe A., Cervantes, Andrés, Gil-Martin, Marta, Wu, Benjamin, Patil, Namrata S., Jin, Yanling, Hoang, Tien, Mendus, Diana, Wen, Xiaohui, Meng, Raymond, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540058/
https://www.ncbi.nlm.nih.gov/pubmed/37768658
http://dx.doi.org/10.1001/jamaoncol.2023.3867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10540058/
https://www.ncbi.nlm.nih.gov/pubmed/37768658
http://dx.doi.org/10.1001/jamaoncol.2023.3867

Ejemplares similares